Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

O. Manzke · SciRah

Researcher profile · Semantic Scholar

O. Manzke

Share profile

O. Manzke — researcher profile on SciRah

h-index: 22
Works: 44
Citations: 2,205

Most-cited papers

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
U. Winkler, M. Jensen, O. Manzke, H. Schulz +2 more
2016371 citations
Semantic Scholar
Vaccination of multiple myeloma patients with idiotype‐pulsed dendritic cells: immunological and clinical aspects
S. Titzer, O. Christensen, O. Manzke, H. Tesch +5 more
2000British Journal of Haematology218 citations
Semantic Scholar
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.
U. Rueffer, K. Breuer, A. Josting, B. Lathan +10 more
2001Annals of Oncology195 citations Open access
Semantic Scholar
Functional Characteristics of ES Cell–derived Cardiac Precursor Cells Identified by Tissue-specific Expression of the Green Fluorescent Protein
E. Kolossov, B. Fleischmann, Qing-Hua Liu, W. Bloch +6 more
1998Journal of Cell Biology189 citations Open access
Semantic Scholar
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
M. R. Weihrauch, O. Manzke, M. Beyer, H. Haverkamp +4 more
2005Cancer Research118 citations Open access
Semantic Scholar
Identification and characterization of embryonic stem cell‐derived pacemaker and atrial cardiomyocytes
E. Kolossov, Zhong J. Lu, I. Drobinskaya, N. Gassanov +7 more
2005The FASEB Journal117 citations
Semantic Scholar
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
M. Jensen, U. Winkler, O. Manzke, V. Diehl +1 more
1998Annals of Hematology115 citations
Semantic Scholar
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
P. Borchmann, R. Schnell, I. Fuss, O. Manzke +7 more
2002Blood111 citations
Semantic Scholar
Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Philipp Holliger, O. Manzke, M. Span, Robert E. Hawkins +7 more
1999Cancer Research85 citations
Semantic Scholar
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Heribert Bohlen, T. Hopff, O. Manzke, A. Engert +4 more
1993Blood83 citations
Semantic Scholar
Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells.
E. Oelmann, H. Herbst, M. Zühlsdorf, O. Albrecht +6 more
2002Blood74 citations
Semantic Scholar
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
H. Bohlen, O. Manzke, B. Patel, G. Moldenhauer +4 more
1993Cancer Research74 citations
Semantic Scholar
Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab
H. Pels, H. Schulz, O. Manzke, E. Hom +2 more
2002Journal of Neuro-Oncology69 citations
Semantic Scholar
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.
O. Manzke, H. Tesch, V. Diehl, H. Bohlen
1997JIM - Journal of Immunological Methods57 citations
Semantic Scholar
Locoregional treatment of low‐grade B‐cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation
O. Manzke, H. Tesch, P. Borchmann, J. Wolf +4 more
2001International Journal of Cancer32 citations Open access
Semantic Scholar
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Heribert Bohlen, O. Manzke, Sandra Titzer, J. Lorenzen +6 more
1997Cancer Research31 citations
Semantic Scholar
Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L
F. Fiore, M. von Bergwelt-Baildon, U. Drebber, M. Beyer +5 more
2006Leukemia and Lymphoma30 citations
Semantic Scholar
Locoregional treatment of low‐grade B‐cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: II. Assessment of cellular immune responses
O. Manzke, H. Tesch, J. Lorenzen, V. Diehl +1 more
2001International Journal of Cancer27 citations Open access
Semantic Scholar
Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
O. Manzke, Orsolina Russello, C. Leenen, V. Diehl +2 more
2001Medical and Pediatric Oncology26 citations
Semantic Scholar
Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation.
Heribert Bohlen, O. Manzke, A. Engert, M. Hertel +3 more
1994JIM - Journal of Immunological Methods25 citations
Semantic Scholar
CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T‐cell reactivity against autologous leukemic cells in pediatric B‐ALL bone marrow
O. Manzke, F. Berthold, K. Huebel, H. Tesch +2 more
1999International Journal of Cancer24 citations Open access
Semantic Scholar
A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL
M. Czuczman, A. Davies, K. Linton, N. Wagner-Johnston +11 more
201423 citations Open access
Semantic Scholar
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
G. Nowakowski, W. Willenbacher, R. Greil, T. Larsen +16 more
2021International journal of hematology16 citations
Semantic Scholar
CD3× anti‐nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors
O. Manzke, Kevin Fitzgerald, P. Holliger, J. Klock +8 more
1999International Journal of Cancer16 citations Open access
Semantic Scholar
Effects of methotrexate on normal articular cartilage in vitro and in vivo
J. Neidel, L. Sova, B. Schroers, F. Sintermann +2 more
1998Annals of the Rheumatic Diseases14 citations Open access
Semantic Scholar
CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma
O. Manzke, S. Titzer, H. Tesch, V. Diehl +1 more
1997Cancer Immunology and Immunotherapy14 citations Open access
Semantic Scholar
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL
G. Nowakowski, W. Willenbacher, R. Greil, T. S. Larsen +15 more
2019Hematological Oncology12 citations Open access
Semantic Scholar
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
G. Nowakowski, W. Willenbacher, R. Greil, T. Larsen +15 more
2019Journal of Clinical Oncology9 citations Open access
Semantic Scholar
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
O. Manzke, S. Titzer, H. Tesch, V. Diehl +1 more
1997Cancer Immunology and Immunotherapy8 citations
Semantic Scholar
Modulation of MUC1 and blood group antigen expression in gastric adenocarcinoma cells by cytokines.
G. Grohmann, P. Schirmacher, O. Manzke, F. Hanisch +2 more
2003Cytokine7 citations
Semantic Scholar
A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
T. Larsen, O. Manzke, Daniel Leibovitz, M. Arbushites
2022Blood4 citations Open access
Semantic Scholar
Treatment of patients with malignant lymphomas with monoclonal antibodies
H. Tesch, A. Engert, O. Manzke, V. Diehl +1 more
2000Bone Marrow Transplantation4 citations
Semantic Scholar
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
L. Sehn, C. Scholz, S. Luminari, A. Salar +8 more
20213 citations
Semantic Scholar
PHASE II STUDY OF DURVALUMAB (ANTI–PD‐L1) COMBINED WITH EITHER R‐CHOP OR LENALIDOMIDE AND R‐CHOP IN PREVIOUSLY UNTREATED, HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
Ulrich Jaeger, N. Kalakonda, H. Everaus, Pierre Fustier +3 more
20172 citations Open access
Semantic Scholar
Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
G. Nowakowski, N. Kalakonda, L. Truemper, H. Everaus +4 more
20171 citations
Semantic Scholar
Monoclonal Antibody Therapy of Patients with Non-Hodgkin´s Lymphomas
H. Tesch, A. Engert, O. Manzke, V. Diehl +2 more
1999Oncology Research and Treatment1 citations
Semantic Scholar
Carcinoembryonic Antigen ( CEA )-specific T-Cell Activation in Colon Carcinoma Induced by Anti-CD 3 3 Anti-CEA Bispecific Diabodies and B 7 3 Anti-CEA Bispecific Fusion Proteins 1
P. Holliger, O. Manzke, M. Span, R. Hawkins +7 more
19991 citations
Semantic Scholar
IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
L. Sehn, C. Scholz, S. Luminari, A. Salar +9 more
20210 citations
Semantic Scholar
INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
K. Hübel, C. Scholz, S. Luminari, A. Salar +9 more
2021Hematological Oncology0 citations Open access
Semantic Scholar
antibodies in combination with bivalent CD28 antibodies leukemia by autologous T cells activated with CD3 x CD19 bispecific Lysis of malignant B cells from patients with B-chronic lymphocytic
H. Bohlen, T. Hopff, O. Manzke, A. Engert +4 more
20110 citations
Semantic Scholar
Role and Extent of Surgery in Multimodality Treatment
J. Classen, M. Bamberg, T. Beinert, T. Werner +38 more
1999Oncology Research and Treatment0 citations Open access
Semantic Scholar
Bispezifische Antikörper — Werkzeuge zur T-Zell Rekrutierung
H. Bohlen, O. Manzke, H. Tesch
19980 citations
Semantic Scholar
E V ects of methotrexate on normal articular cartilage in vitro and in vivo
J. Neidel, L. Sova, B. Schroers, F. Sintermann +2 more
19980 citations
Semantic Scholar
ects of methotrexate on normal articular cartilage in vitro and in vivo
J. Neidel, L. Sova, B. Schroers, F. Sintermann +2 more
19980 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Bohlen×19
Invite
H. Bohlen — researcher profile on SciRah
V. Diehl×12
Invite
V. Diehl — researcher profile on SciRah
H. Tesch×10
Invite
H. Tesch — researcher profile on SciRah
Heribert Bohlen×6
Invite
Heribert Bohlen — researcher profile on SciRah

×5

Invite

A. Engert — researcher profile on SciRah

Invite

A. Engert — researcher profile on SciRah

Volker Diehl×5

Invite

Volker Diehl — researcher profile on SciRah

Invite

H. Everaus — researcher profile on SciRah

N. Kalakonda×5

Invite

N. Kalakonda — researcher profile on SciRah

B. Fleischmann×4

Invite

B. Fleischmann — researcher profile on SciRah

Invite

S. Titzer — researcher profile on SciRah

Invite

V. Diehl — researcher profile on SciRah